Bristol-Myers Squibb Company Stock price

Equities

BMY

US1101221083

Pharmaceuticals

Market Closed - Nyse 04:00:02 2024-03-28 pm EDT 5-day change 1st Jan Change
54.23 USD +1.84% Intraday chart for Bristol-Myers Squibb Company +5.12% +5.69%
Sales 2024 * 45.85B Sales 2025 * 46.35B Capitalization 110B
Net income 2024 * 7.19B Net income 2025 * 10.52B EV / Sales 2024 * 3.14 x
Net Debt 2024 * 33.89B Net Debt 2025 * 25.64B EV / Sales 2025 * 2.92 x
P/E ratio 2024 *
14.4 x
P/E ratio 2025 *
9.74 x
Employees 34,100
Yield 2024 *
4.48%
Yield 2025 *
4.68%
Free-Float 69.08%
More Fundamentals * Assessed data
Dynamic Chart
Bristol-Myers Solicits Proxies from the Shareholders CI
Bristol-Myers Solicits Proxies from the Shareholders CI
Bristol Myers Squibb Drug Misses Endpoint in Crohn's Disease Trial DJ
Bristol-Myers Squibb's Phase 3 Trial of Crohn's Disease Treatment Fails to Meet Primary Endpoint MT
Bristol Myers' bowel disease drug fails to meet main goal in late-stage study RE
Bristol Myers Squibb Announces Pivotal KRYSTALl-12 Confirmatory Trial Evaluating KRAZATI Meets Primary Endpoint of Progression-Free Survival for Patients with Pretreated KRASG12C-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer CI
Bristol Myers Squibb Provides Update on the First Phase 3 YELLOWSTONE Trial Evaluating Oral Zeposia in Patients with Moderate to Severe Active Crohn's Disease CI
Bristol Myers: initiatives to advance health equity CF
Bristol Myers Squibb to Present Data at the American College of Cardiology Annual Scientific Session 2024 CI
Q32 Bio Inc. announced that it has received $42 million in funding from a group of investors CI
Bristol Myers: Abecma approved by the European Union CF
Bristol-Myers Squibb's Multiple Myeloma Treatment Gets European Commission Approval MT
Bristol Myers Squibb Gets EU OK for Cancer Treatment DJ
Bristol Myers Squibb?s Abecma (idecabtagene vicleucel) Becomes First CAR T Cell Therapy Approved in the European Union in Earlier Lines for Triple-Class Exposed Relapsed and Refractory Multiple Myeloma CI
Bristol-Myers Squibb's Phase 3 Hepatocellular Carcinoma Study Meets Overall Survival Goal MT
More news
1 day+1.84%
1 week+5.12%
Current month+6.86%
1 month+6.50%
3 months+5.88%
6 months-6.73%
Current year+5.69%
More quotes
1 week
51.91
Extreme 51.91
54.48
1 month
50.44
Extreme 50.44
55.04
Current year
47.58
Extreme 47.58
55.04
1 year
47.58
Extreme 47.58
71.07
3 years
47.58
Extreme 47.58
81.44
5 years
42.48
Extreme 42.48
81.44
10 years
42.48
Extreme 42.48
81.44
More quotes
Managers TitleAgeSince
Chief Executive Officer 53 15-01-31
Chairman 59 99-12-31
Director of Finance/CFO 55 19-11-19
Members of the board TitleAgeSince
Director/Board Member 66 19-11-19
Director/Board Member 59 16-03-31
Director/Board Member 59 20-08-31
More insiders
Date Price Change Volume
24-03-28 54.23 +1.84% 14,348,196
24-03-27 53.25 +1.33% 13,077,608
24-03-26 52.55 +0.57% 9,951,952
24-03-25 52.25 +0.62% 12,348,068
24-03-22 51.93 +0.66% 11,727,720

Delayed Quote Nyse, March 28, 2024 at 04:00 pm EDT

More quotes
Bristol-Myers Squibb Company est spécialisé dans le développement, la fabrication et la commercialisation de produits pharmaceutiques. Les produits sont destinés au traitement des cancers, des maladies cardio-vasculaires, de l'hépatite, des maladies immunitaires et des désordres psychiatriques. The United States account for 70.1% of net sales.
Calendar
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B
More Ratings
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
27
Last Close Price
54.23 USD
Average target price
56.41 USD
Spread / Average Target
+4.02%
Consensus
  1. Stock
  2. Equities
  3. Stock Bristol-Myers Squibb Company - Nyse